false 0000882796 0000882796 2025-01-13 2025-01-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 13, 2025

 

BioCryst Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware 000-23186 62-1413174
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)

 

4505 Emperor Blvd., Suite 200

Durham, North Carolina 27703

(Address of Principal Executive Offices) (Zip Code)

 

(919) 859-1302

(Registrant’s telephone number, including area code)

 

________________________________________

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock BCRX Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 7.01. Regulation FD Disclosure.

 

As previously announced, BioCryst Pharmaceuticals, Inc. (the “Company”) will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025 at 6:00 p.m. ET. The slides prepared in connection with this upcoming webcast presentation, which include information relating to our drug discovery and development programs, will be posted on Monday, January 13, 2025, in the Events & Presentations section of the Company’s Investor Relations website at https://ir.biocryst.com/news-events/events.

 

The Company routinely posts important information, including news releases, announcements and other statements about its business and results of operations, that may be deemed material to investors on the Company’s Investors Relations website at https://ir.biocryst.com/news-events/press-releases. The Company uses its website as a means of disclosing material, nonpublic information and for complying with the Company’s disclosure obligations under Regulation FD. Investors should monitor the Company’s Investor Relations website in addition to following the Company’s press releases, filings with the SEC, public conference calls and webcasts.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Date: January 13, 2025 BioCryst Pharmaceuticals, Inc.
 

 

 

By: 

 

 

/s/ Alane Barnes

 

    Alane Barnes
    Chief Legal Officer

 

 

 

 

 

 

 

 

 

 

 

v3.24.4
Cover
Jan. 13, 2025
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 13, 2025
Entity File Number 000-23186
Entity Registrant Name BioCryst Pharmaceuticals, Inc.
Entity Central Index Key 0000882796
Entity Tax Identification Number 62-1413174
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 4505 Emperor Blvd.
Entity Address, Address Line Two Suite 200
Entity Address, City or Town Durham
Entity Address, State or Province NC
Entity Address, Postal Zip Code 27703
City Area Code (919)
Local Phone Number 859-1302
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol BCRX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025 Click aqui para mais gráficos BioCryst Pharmaceuticals.
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025 Click aqui para mais gráficos BioCryst Pharmaceuticals.